A New Cancer Immunotherapy Is Coming: Blocking Macrophage Checkpoints

Activating tumor-associated macrophages through their checkpoint CD47 is emerging as a new and effective cancer immunotherapy.
The tumor microenvironment, plays an important role in cancer cell proliferation, spread and development of drug resistance . The tumor microenvironment contains cells suppressing the immune system and immune cells that the tumor has begun to use for its own benefit . Macrophages are important cells in the tumor microenvironment. Normally, their task is to provide the first defense against pathogenic microorganisms such as bacteria and against tumors. They do this through phagocytosis and certain extracellular mechanisms.
In the figure below, a macrophage (the large orange cell) is shown attacking and destroying bacteria (small green cells).

Related Topic:
However, as a tumor progresses, it uses the immune system and macrophages, one of its components, for its own benefit. Macrophages then become tumor-associated macrophages .

In the figure above, the tumor-supporting and antitumor properties of macrophages are shown. These important immune cells can therefore act either to support or oppose tumors, depending on the situation.
Macrophages have antitumor or protumor properties according to cancer treatments applied and their activation state. As a tumor progresses, tumor-associated macrophages suppress immunity, support metastasis and invasion (spread into tissues), support cancer stem cells, and make fibroblasts and the extracellular matrix (the environment between cells) tumor-supporting. How do tumor-associated macrophages arise?
In cancer cells, C-MYC is a highly active oncogene enabling aggressive cancer cell proliferation. The C-MYC gene also increases CD47 gene activity. The CD47 gene produces the cell-surface CD47 receptor receptor. CD47 on cancer cells binds to the macrophage SIRPA protein. Then, the macrophage sees the cancer cell as a friend and does not attack. This is why CD47 is called the macrophage checkpoint .
Monoclonal antibodies targeting CD47 have been developed to prevent this binding. Anti-CD47 and, currently used for some leukemias and lymphomas , anti-CD20 are being explored together as a new cancer treatment strategy.
For this purpose, a phase-1b clinical trialevaluated Hu5F9-G4 (anti-CD47) and rituximab (anti CD20) in patients with large B-cell lymphoma and follicular lymphoma resistant to standard treatments. The resulting complete response ratewas 33 percent in large B-cell lymphoma and 43 percent in follicular lymphoma. As expected, anti-CD47 treatment causes a manageable adverse effect such as anemia.
The success achieved is related to activation of macrophages' direct toxicity (appropriately activated macrophages have a direct toxic/harmful effect on cancer cells).
Tumor cell genetic instability (high tumor antigen density), current T-cell-targeted checkpoint inhibitor immunotherapy has its success determined importantly by this factor, whereas macrophage checkpoint blockade does not depend on tumor antigens.
Combining macrophage blockade with T-cell blockade may provide effective cancer treatment by activating both innate and adaptive immunity. The main challenge is identifying which patients will respond to this new immunotherapy. Interestingly, dense tumor infiltration by macrophages has been associated with a poor prognosis (disease course).
In the figure below, monocytes becoming tumor-associated macrophages and then traveling to the tumor microenvironment are shown, along with how they support the tumor (invasion, metastasis, angiogenesis, immunosuppression).

Sources
Macrophage Checkpoint Blockade in Cancer — Back to the Future.
NEJM, 1 November 2018
Was this article helpful?
Your feedback helps us improve our content.





Reader comments
Share your comment
Your name and comment are published only after administrator approval. Your email address is never shown to visitors.
Be the first to comment.